

CURRICULUM VITAE

Wei Shen Tan, MD, PhD, FRCS

Version date: 08/28/2024

Proposed for: Appointment as Assistant Professor, Clinical Scholar Track, Department of Urology, Yale School of Medicine

Term: Primary Appointment: beginning 09/01/2024

School: Yale School of Medicine

Education:

5/2021 **FRCS (Urol)**, Royal College of Surgeons of England, London, UK

10/2015-03/2019 **PhD**, Uro-oncology, University College London, London, UK

09/2004-07/2010 **MD**, Cardiff University, Cardiff, UK

09/2007-06/2008 **BSc**, Clinical Sciences, University College London, London, UK

Career/Academic Appointments:

9/2024-present **Assistant Professor of Urology**, Yale New Haven Hospital, New Haven, CT

10/2024-present **Honorary Associate Professor of Urology**, University College London, London, UK

07/2022-06/2024 **Society of Urologic Oncology (SUO) Fellow**, University of Texas MD Anderson Cancer Center, Houston, TX

10/2021-07/2022 **Urologic Oncology Robotics Fellow**, University College London Hospitals, London, UK

10/2014-07/2022 **Urology Resident**, London School of Surgery (North London) [University College London, Royal Free Hospital, Imperial College Healthcare rotation]

10/2012-10/2014 **Academic Clinical Fellow in Urology** (Urology academic track program), University College London, London, UK

07/2010-07/2012 **Academic Foundation Program in Urology** (Urology internship academic program), University College London, London, UK

Board Certification:

07/2022 Certificate of Completion of Specialist Training (CCT) in Urology (UK Board Certification)

Professional Honors & Recognition:

International/National/Regional

2023 British Journal of Urology International- Silver Reviewer Award 2022

2022 Society of Urologic Oncology (SUO) Young Urologic Oncologist (YOU) 2022 Paper of the Year Award- 1st Runner up

2022 European Urology Oncology SoMe Award (highest PlumX metrics paper for October)

2022 British Journal of Urology International- Reviewer of the month (November)

2019 British Journal of Urology International- Top Downloaded Paper 2018-2019

2019 British Journal of Urology International- Bronze Reviewer Award 2018

2019 Urology Association of Asia Congress- 1st place oral presentation (Oncology Session-Renal)

2019 European Association of Urology- Best poster (Urine, serum and tissue diagnostic innovations in urothelial cancer session)

2019 European Association of Urology- Best poster (Outcomes of partial nephrectomy: Kidney function and beyond)

Wei Shen Tan, MD, PhD, FRCS

2018	Malcolm Coptcoat spring short papers, Royal Society of Medicine- Malcolm Coptcoat prize nominee
2018	Malcolm Coptcoat spring short papers, Royal Society of Medicine- BAUS academic prize nominee
2017	American Urology Association- Best Abstract (Bladder Cancer: Basic Research & Pathophysiology I)
2016	Enhanced Recovery after Surgery Society (UK)-2nd Prize for best paper
2016	Asia Congress of Urology- Best abstract (Oncology)
2016	17th Annual Network for the Advancement of Patient Blood Management, Hemostasis and Thrombosis (NATA) Symposium- Best Academic Paper nominee
2015	European Urology Association- 2nd Prize for Best Abstract (Oncology)
2014	British Association of Urological Surgeons Annual Meeting 2014- Best academic paper nominee
2014	British Association of Urological Surgeons Annual Meeting 2014- Best academic paper nominee

University

2010	Certificate in excellence in General Practice
2008	Dean's List of the Faculty of Life Sciences (BSc result)
2008	Nominated for the HAB Simons Prize (Best BSc project)
2007	Distinction in Intermediate MB (MD Year 2 & 3 result)
2005	Distinction in Primary MB (MD Year 1 result)

Grant/Clinical Trials History:

Current Grants

Agency:	National Institute of Health Research, UK
ID#:	Heath Technology Assessment (HTA) scheme. Ref: NIHR160459
Title:	Combination chemotherapy versus Bacillus Calmette-Guérin (BCG) for high-risk non-muscle invasive bladder cancer– a phase III multi-center randomized controlled trial (COBRA)
CI:	Wei Shen Tan, MD, PhD, FRCS; Emma Hall, PhD
Percent effort:	5%
Total costs:	£3,315,716.52
Project period:	01/01/2025 – 12/31/2031

Past Grants

Agency:	The Urology Foundation
ID#:	NA
Title:	Optimizing the Investigation of Hematuria and Bladder Cancer
CI:	Wei Shen Tan, MD, PhD, FRCS
Percent effort:	100%
Total costs:	£81,839 (salary support and consumables)
Project period:	05/01/2016 – 01/31/2021

Agency:	Mason Medical Research
ID#:	NA
Title:	Prospective Observational Study to Determine the Ability of UroMark to Detect Bladder Cancer Recurrence in Patients undergoing Surveillance Cystoscopy (SURVEY).

CI: Wei Shen Tan, MD, PhD, FRCS
Percent effort: 100%
Total costs: £44,563 (salary support and consumables)
Project period: 06/01/2017 – 05/31/2018

Agency: The Urology Foundation
ID#: NA
Title: INPP4B a biomarker to predict poor prognosis in high grade bladder cancer
CI: Wei Shen Tan, MD, PhD, FRCS
Percent effort: 100%
Total costs: £50,000 (salary support and consumables)
Project period: 10/01/2014 – 09/30/2015

Past Clinical Trials Involvement

Agency: Cancer Research UK, Combat Medical
ID#: ISRCTN 23639415
Title: Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomized Controlled Trial
CI: John D Kelly, MD
Role: Trial research fellow
Project period: 5/1/2024 – 6/30/2023

Agency: Medical Research Council
ID#: NCT02676180, NCT02781428
Title: Prospective multicenter observational study to validate the UroMark assay for the detection of bladder cancer from urinary cells (DETECT I & II)
CI: John D Kelly, MD
Role: Trial research fellow
Project period: 04/30/2016 – 4/30/2021

Agency: Cancer Research UK, Medical Enterprise Europe
ID#: NCT01094964
Title: Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomized Controlled Trial
CI: John D Kelly, MD
Role: Trial research fellow
Project period: 05/01/2010 – 01/31/2019

Agency: Cancer Research UK
ID#: ISRCTN84681538
Title: A Randomized Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder
CI: John D Kelly, MD
Role: Trial research fellow
Project period: 11/1/2007 – 4/30/2019

Invited Speaking Engagements, Presentations, Symposia & Workshops Not Affiliated with Yale:

International/National

1. **“IR NMIBC: Disease Stratification & Implications in Trial Inclusion”** Plenary presentation. International Bladder Cancer Group (IBCG) 2024 retreat, Houston, TX.
2. **“Optimizing Perioperative Outcomes: Enhanced Recovery and Robotic Cystectomy.”** Plenary presentation. AUA- World Chinese Urological Society (WCUS) section, San Antonio, TX, 2024.
3. SIU Innovators session (Co-chair). SIU, Montreal, Canada, 2022.
4. **“Adjuvant intravesical chemohyperthermia versus passive chemotherapy in patients with intermediate risk non-muscle invasive bladder cancer (HIVEC II): A phase II, open label, randomized controlled trial.”** UroToday, 2022.
5. **“Intermediate risk non muscle invasive bladder cancer: updated consensus definition and management recommendations from the International Bladder Cancer Group (IBCG).”** UroToday, 2022.
6. **“DETECT I & II: Optimizing the investigation of hematuria and non-muscle invasive bladder cancer surveillance.”** Plenary presentation. British Association of Urological Surgeons (BAUS) Section of Trainees (BSOT) meeting, Leeds, UK, 2020.
7. **“Debate 1- NMIBC: Intravesical Therapy: Urinary Markers are Useful in Management of Bladder Cancer.”** Plenary presentation. SIU, Athens, Greece, 2019.
8. **“Approach to Hematuria: the latest Evidence.”** Plenary presentation. Urological Association of Asia (UAA), Kuala Lumpur, Malaysia, 2019.
9. **“Device assisted therapies for non-muscle invasive bladder cancer.”** Harvard/ Brigham and Women Combined Urology Grand Rounds. Boston, MA, 2018.
10. **“Hematuria: Controversies in Everyday Practice- Can CT intravenous urogram be replaced with renal tract ultrasound for non-visible hematuria?”** Plenary presentation. British Association of Urological Surgeons (BAUS) meeting, Liverpool, UK, 2018.
11. **“Device assisted therapies for bladder cancer.”** Plenary presentation. American Urological Association (AUA)- World Chinese Urological Society (WCUS) section, San Francisco, CA, 2018.
12. **“Robotic Cystectomy: Does the Robot Matter.”** Plenary presentation. 3rd International Symposium of Advanced Robotic Techniques in Urology, London, UK, 2016.
13. **“A New Urine Test for the Hematuria Clinic.”** Plenary presentation. British Association of Urological Surgeons (BAUS) Oncology, Cardiff, UK, 2016.

Peer-Reviewed Presentations & Symposia Given at Meetings Not Affiliated with Yale:

International/National

1. **The International Bladder Cancer Group intermediate-risk non-muscle invasive bladder cancer (IBCG IR-NMIBC) scoring system predicts the need for intervention for patients on active surveillance.** American Urological Association (AUA). San Antonio, TX. 2024 (Moderated poster).
2. **The Hematuria Cancer Risk Score: a validation study demonstrating reduction in the number needed to investigate while preserving fidelity of cancer detection.** American Urological Association (AUA). Chicago, IL. 2023 (Podium presentation).
3. **Bladder sparing treatment in patients with BCG unresponsive non-muscle invasive bladder cancer: an analysis of long-term survival outcomes.** American Urological Association (AUA). Chicago, IL. 2023 (Podium presentation).

4. **Adjuvant intravesical chemohyperthermia versus passive chemotherapy in patients with intermediate risk non-muscle invasive bladder cancer (HIVEC II): A phase II, open label, randomized controlled trial.** Society of Urologic Oncology meeting. San Diego, CA. 2022 (Poster presentation).
5. **Factors associated with high-quality surgery following radical cystectomy: Analysis of the British Association of Urological Surgeons (BAUS) cystectomy audit.** European Association of Urology (EAU). Virtual meeting. 2021 (Moderated poster).
6. **Intravesical chemohyperthermia (HIVEC-E) in BCG unresponsive non-muscle invasive bladder cancer patients: Oncological outcomes of a multi-center European registry.** European Association of Urology (EAU). Virtual meeting. 2020 (Moderated poster).
7. **Defining factors associated with quality surgery following radical cystectomy: Analysis of the British Association of Urological Surgeons (BAUS) cystectomy audit.** European Association of Urology (EAU). Virtual meeting. 2020 (Moderated poster).
8. **Comparing long-term outcomes following radical and partial nephrectomy for cT1 renal cell carcinoma in young and healthy individuals.** Urological Association of Asia (UAA) Congress. Kuala Lumpur, Malaysia. 2019 (Oral presentation).
9. **Development and external validation of the hematuria cancer risk score to identify patient at risk of harboring cancer.** Urological Association of Asia (UAA) Congress. Kuala Lumpur, Malaysia. 2019 (Oral presentation).
10. **Oncological outcomes of BCG unresponsive non-muscle invasive bladder cancer patients treated with chemohyperthermia: A multicenter European retrospective analysis.** British Association of Urological Surgeons (BAUS) Annual Meeting. Glasgow, UK. 2019 (Moderated poster)
11. **Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A retrospective cohort study.** British Association of Urological Surgeons (BAUS) Annual Meeting. Glasgow, UK. 2019 (Moderated poster).
12. **Comparing long-term outcomes following radical and partial nephrectomy for cT1 renal cell carcinoma in young and healthy individuals.** British Association of Urological Surgeons (BAUS) Annual Meeting. Glasgow, UK. 2019 (Moderated poster)
13. **Development and external validation of the hematuria cancer risk score to identify patient at risk of harboring cancer.** British Association of Urological Surgeons (BAUS) Annual Meeting. Glasgow, UK. 2019 (Moderated poster).
14. **Variation in positive surgical margin status following radical prostatectomy for pT2 prostate cancer.** British Association of Urological Surgeons (BAUS) Annual Meeting. Glasgow, UK. 2019 (Moderated poster).
15. **Oncological outcomes of BCG unresponsive non-muscle invasive bladder cancer patients treated with chemohyperthermia: A multicenter European retrospective analysis.** American Urological Association (AUA). Chicago, IL. 2019 (Podium).
16. **Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A retrospective cohort study.** American Urological Association (AUA). Chicago, IL. 2019 (Podium).
17. **Development and external validation of the hematuria cancer risk score to identify patient at risk of harboring cancer.** American Urological Association (AUA). Chicago, IL. 2019 (Podium).

18. **Variation in positive surgical margin status following radical prostatectomy for pT2 prostate cancer.** American Urological Association (AUA). Chicago, IL. 2019 (Moderated poster).
19. **Comparing long-term outcomes following radical and partial nephrectomy for cT1 renal cell carcinoma in young and healthy individuals.** European Association of Urology (EAU). Barcelona, Spain. 2019 (Moderated poster).
20. **Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A retrospective cohort study.** European Association of Urology (EAU). Barcelona, Spain. 2019 (Moderated poster).
21. **Development and external validation of the hematuria cancer risk score to identify patient at risk of harboring cancer.** European Association of Urology (EAU). Barcelona, Spain. 2019 (Moderated poster).
22. **Mix methods approach to determine patients' perspectives on the acceptability of a urinary biomarker test in replacement of cystoscopy for bladder cancer surveillance.** European Association of Urology (EAU). Barcelona, Spain. 2019 (Moderated poster).
23. **Variation in positive surgical margin status following radical prostatectomy for pT2 prostate cancer.** European Association of Urology (EAU). Barcelona, Spain. 2019 (Moderated poster).
24. **Evaluating the cost of surveillance for non-muscle invasive bladder cancer: An economic analysis based on risk categories.** European Association of Urology (EAU). Barcelona, Spain. 2019 (Moderated poster).
25. **Who should be investigated for hematuria? A prospective observational study of 3556 patients.** British Association of Urological Surgeons (BAUS) Annual Meeting. Liverpool, UK. 2018 (Moderated poster).
26. **Can CT intravenous urogram be replaced with renal tract ultrasound for non-visible hematuria?** British Association of Urological Surgeons (BAUS) Annual Meeting. Liverpool, UK. 2018 (Moderated poster).
27. **Can renal tract ultrasound replace CT urography for the evaluation of microscopic hematuria? Results of a prospective observational study.** American Urological Association (AUA). San Francisco, CA. 2018 (Moderated poster).
28. **Who should be evaluated for hematuria? A comparison of international guidelines.** American Urological Association (AUA). San Francisco, CA. 2018 (Moderated poster).
29. **Does urinary cytology have a role in hematuria investigations? Results of a prospective observational study (DETECT I).** American Urological Association (AUA). San Francisco, CA. 2018 (Moderated poster).
30. **Can renal tract ultrasound replace CT urogram in patients investigated for non-visible hematuria?** Malcolm Coptcoat spring short paper and AUS academic research meeting, Royal College of Medicine, London, UK. 2018 (Oral presentation).
31. **Who should be investigated for hematuria? Results of a contemporary prospective observational study of 3556 patients.** Malcolm Coptcoat spring short paper and AUS academic research meeting, Royal College of Medicine, London, UK. 2018 (Oral presentation).
32. **What is the role of urinary cytology as part of haematuria investigations? Results of a prospective observational study (DETECT I).** Coptcoat spring short paper and AUS academic research meeting, Royal College of Medicine, London, UK. 2018 (Poster presentation).

33. **Radofrequency-induced thermochemotherapy effect (RITE) plus mitomycin versus a second course of bacillus Calmette Guerin (BCG) or institutional standard in patients with recurrence of non-muscle invasive bladder cancer following induction or maintenance BCG therapy (HMYN): A open-label, multicenter, phase III randomised controlled trial.** American Urological Association (AUA). Boston, MA. 2017 (Oral presentation).
34. **Absence of evidence is not evidence of absence: Normal areas on MRI could harbor significant tumour.** American Urological Association (AUA). Boston, MA. 2017 (Oral presentation).
35. **Safety & tolerability analysis of hyperthermic intravesical mitomycin to mitomycin alone in HIVEC I & HIVEC II: An analysis of 307 patients.** American Urological Association (AUA). Boston, MA. 2017 (Moderated poster).
36. **Health related quality of life after radical cystectomy and urinary diversion: Open versus robotic assisted techniques.** American Urological Association (AUA). Boston, MA. 2017 (Moderated poster).
37. **Radiofrequency-induced thermo-chemotherapy effect plus mitomycin versus a second course of bacillus Calmette-Guérin (BCG) or institutional standard in patients with recurrence of non-muscle invasive bladder cancer following induction or maintenance BCG therapy (HYMN): A phase III, open-label, randomized controlled trial.** European Association of Urology (EAU). London, UK. 2017 (Moderated poster).
38. **Safety and tolerability analysis of hyperthermic intravesical mitomycin to mitomycin alone in HIVEC I and HIVEC II: An interim analysis of 307 patients.** European Association of Urology (EAU). London, UK. 2017 (Moderated poster).
39. **Enhanced recovery enhances reduction of length of stay in patients treated with robotic assisted radical cystectomy with intracorporeal urinary diversion.** European Association of Urology (EAU). London, UK. 2017 (Moderated poster).
40. **Low INPP4B expression predicts poor prognosis in locally advanced and metastatic bladder cancer.** British Association of Urological Surgeons (BAUS) Annual Meeting. Liverpool, UK. 2016 (Moderated poster).
41. **Complications following robotic assisted radical cystectomy (RARC) with intracorporeal urinary diversion: An analysis of 90-day outcomes stratified according to type of urinary diversion.** British Association of Urological Surgeons (BAUS) Annual Meeting. Liverpool, UK. 2016 (Moderated poster).
42. **Perioperative Blood Transfusion is associated with Postoperative Complications after Intracorporeal Robotic Assisted Radical Cystectomy.** 17th Annual Network for the Advancement of Patient Blood Management, Hemostasis and Thrombosis Symposium, Dublin, Ireland. 2016 (Moderated poster)
43. **Oncological Outcomes and Recurrence Sites Following Intracorporeal Robotic Cystectomy versus Open Radical Cystectomy: An Analysis of 184 patients.** World Congress of Endourology. London, UK. 2015 (Moderated poster).
44. **Robotic Cystectomy with Intracorporeal Diversion is Better Tolerated by Patients with Low Cardiorespiratory Fitness: A Cohort Study.** World Congress of Endourology. London, UK. 2015 (Moderated poster)
45. **Is NCCT the Most Appropriate Primary Imaging Modality in Females with Suspected Renal Colic?** World Congress of Endourology. London, UK. 2015 (Moderated poster).

46. **Oncological Outcomes and Recurrence Sites Following Intracorporeal Robotic Cystectomy versus Open Radical Cystectomy: An Analysis of 184 patients.** British Association of Urological Surgeons (BAUS) Annual Meeting. Manchester, UK. 2015 (Podium presentation).
47. **Management of node positive bladder cancer following neo-adjuvant chemotherapy and radical cystectomy: A survey of current UK practice.** Société Internationale d'Urologie. Glasgow, UK. 2014 (Moderated poster).
48. **INPP4B Knockdown Confers Cisplatin Sensitivity in Bladder Cancer.** British Association of Urological Surgeons (BAUS) Annual Meeting. Liverpool, UK. 2014 (Podium presentation).
49. **INPP4B Knockdown Confers Cisplatin Sensitivity in Bladder Cancer.** European Association of Urology (EAU). Stockholm, Sweden. 2014 (Moderated poster).
50. **DNA Methylation as a Biomarker to Predict Neo-adjuvant Cisplatin Based Chemotherapy Resistance in Bladder Cancer.** British Association of Urological Surgeons (BAUS) Annual Meeting Manchester, UK. 2013 (Moderate poster).
51. **Epigenetic Alterations associated with Neo-adjuvant Chemotherapy Resistance in Bladder Cancer.** European Association of Urology (EAU). Milan, Italy. 2013 (Moderated poster).
52. **Biochemical Recurrence after Radical Radiotherapy for Localized Prostate Cancer - The Cardiff Experience.** UK Radiation Oncology Conference, Manchester, UK. 2010 (Poster).
53. **Overactive Bladder (OAB) and its association with Prostatic Parameters.** 4th Japan-Asean Men's Health Meeting, Kota Kinabalu, Malaysia. 2010 (Podium presentation).
54. **Altered Urothelial ATP Signaling in Human Overactive Bladder (OAB) Patients.** Physiology Society Meeting. Dublin, Ireland. 2009 (Poster presentation).
55. **Relationship of SLOH, ED and LUTS- Experiences of Urban Dwelling Men.** 8th ASIAN Congress of Urology. Bali, Indonesia. 2006 (Oral presentation).

Professional Service

Peer Review Groups/Grant Study Sections:

2022- present Member, International Bladder Cancer Group (IBCG).

Journals:

Editorial Boards

2022- present British Journal of Urology International

2020- present Journal of Men's Health

Reviewer

New England Journal of Medicine, Journal of the American Medical Association (JAMA), British Medical Journal (BMJ), European Urology, European Urology Oncology, JAMA Open Network, Journal of Urology, British Journal of Urology International Compass, Urologic Oncology, PLOS One, Cancer Biomarkers, Frontiers in Medicine, Therapeutic Advances in Urology, Urologia Internationalis, BMC Urology, Scandinavian Journal of Urology, Asian Journal of Urology, Minerva Urologica e Nefrologica

Professional Organizations:

2022- present International Bladder Cancer Network (IBCN)- Member

2022- present	International Bladder Cancer Group (IBCG)- Member
2021- present	SIU Innovators Committee- Member
2021- 2022	European Association of Urology- Young Academic Urologists Urothelial Cancer working party member
2021- present	American Association of Urology- Member
2015- present	Société Internationale d'Urologie- Member
2014- present	British Association of Urological Surgeons- Member
2011- present	European Association of Urology- Member

Public Service / Media Presence:

Media Presence:

2024	Device-Assisted Therapies for Bladder Cancer: History, Mechanisms, and Clinical Trials. UroToday (Didactics). [URL: https://rb.gy/qmf8n]
2023	Long-Term Survival Outcomes in Patients with BCG Unresponsive Non-Muscle Invasive Bladder Cancer: Evaluating Bladder-Sparing Treatment. UroToday (Interview). [URL: https://rb.gy/lvd61]
2023	Bladder Sparing Treatment in Patients with BCG Unresponsive Non-Muscle Invasive Bladder Cancer: An Analysis of Long-Term Survival Outcomes. UroToday. [URL: https://rb.gy/cr0k8]
2022	HIVEC-II Phase 2 Trial Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk NMIBC. UroToday (Interview). [URL: https://rb.gy/fgl7r]
2022	Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group: Intermediate-risk Non-muscle-invasive Bladder Cancer. UroToday (Interview). [URL: https://rb.gy/upd6s]
2022	Bladder-Sparing Options for BCG-Unresponsive Bladder Cancer. Oncology Learning Network (Interview). [URL: https://rb.gy/htavp]
2022	The role of guidelines in the management of intermediate-risk NMIBC. Urology Times (Interview). [URL: https://rb.gy/9taas]
2019	Debate- Urinary Markers Are Useful in Management of Bladder Cancer. UroToday. [URL: https://rb.gy/n5trd]
2019	Development and External Validation of the Hematuria Cancer Risk Score to Identify Patient at Risk of Harboring Cancer. UroToday. [URL: https://rb.gy/ozsqv]
2019	Variation in Positive Surgical Margin Status Following Radical Prostatectomy for pT2 Prostate Cancer. UroToday. [URL: https://rb.gy/c3io5]

Bibliography:

Peer-Reviewed Original Research

1. Taylor JI, Kamat AM, O'Donnell MA, Annapureddy D, Howard J, **Tan WS**, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black AJ, Kanabur P, Roumigué M, Lerner S, Black PC, Raman JD, Preston MA, Steinberg G, Huang W, Li R, Packiam VT, Woldu SL, Lotan Y. **Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer.** *BJU Int.* 2024 Aug 25. doi: 10.1111/bju.16509. PMID: 39183466.

2. Grajales V, Contieri R, **Tan WS**, Flores M, Schultz M, Pinochet R, Bustamante A, Kamat AM, Fernández MI. **Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile.** *Bladder Cancer*. 2023 Dec 13;9(4):327-334. PMID: 38994240.
3. Myers AA, **Tan WS**, Grajales V, Hwang H, Bree KK, Navai N, Lee BH, Dinney CPN, Kamat AM. **Challenging the Paradigm of "BCG-unresponsive" Bladder Cancer: Does Additional Bacillus Calmette-Guérin Have an Effect?** *Eur Urol*. 2024 Jun 14:S0302-2838(24)02409-6. PMID: 38879371.
4. **Tan WS**, Ahmad A, Zhou Y, Nathan A, Ogunbo A, Gbolahan O, Kallam N, Smith R, Khalifeh M, Tan WP, Cohen D, Volanis D, Walter FM, Sasieni P, Kamat AM, Kelly JD. **Hematuria Cancer Risk Score with Ultrasound Informs Cystoscopy Use in Patients with Hematuria.** *Eur Urol Oncol*. 2024 May 28:S2588-9311(24)00134-2. PMID: 38811250.
5. Lobo N, Duan Z, Sood A, **Tan WS**, Grajales V, Contieri R, Lindskrog SV, Dyrskjot L, Zhao H, Giordano SH, Williams SB, Bree KK, Kamat AM. **Association of Age with Non-muscle-invasive Bladder Cancer: Unearthing a Biological Basis for Epidemiological Disparities?** *Eur Urol Oncol* 2024 Jan 31:S2588-9311(24)00036-1. PMID: 38302322.
6. Hudson J, Cruickshank M, Quinton R, Aucott L, Wu F, Grossmann M, Bhasin S; Snyder P; Ellenberg S, Grossmann M, Travison T, Brock GB, Gianatti E, van der Schouw Y; Emmelot-Vonk M, Giltay E, Hackett G, Ramachandran S, Svartberg J, Hildreth K, Antonic KG, Tenover JL, Tan HM, Ho CCK, **Tan WS**, Marks L, Ross R, Schwartz R, Manson P, Roberts S, Anderson M, Magnussen LV, Aceves-Martins M, Gillies K, Hernandez R, Oliver N, Dhillon W, Bhattacharya S, Brazzelli M, Jayasena C. **Symptomatic benefits of testosterone treatment in patient subgroups: a systematic review, individual participant data meta-analysis, and aggregate data meta-analysis.** *Lancet Healthy Longev* 2023. 4 (10): E561-572. DOI: [https://doi.org/10.1016/S2666-7568\(23\)00169-1](https://doi.org/10.1016/S2666-7568(23)00169-1). PMID: 37804846.
7. Contieri R, Hensley P, **Tan WS**, Grajales V, Bree K, Nogueras-Gonzalez GM, Lee BH, Navai N, Dinney CP, Kamat AM. **Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy.** *Eur Urol Onc*. 2023 Aug 7;S2588-9311(23)00157-8. PMID: 37558542.
8. **Tan WS**, Contieri R, Buffi NM, Lughezzani G, Grajales V, Soloway M, Casale P, Hurle R, Kamat AM. **International Bladder Cancer Group Intermediate-risk Non-muscle Invasive Bladder Cancer (IBCG IR-NMIBC) Scoring System Predicts Outcomes of Patients on Active Surveillance.** *J Urol*. 2023 Aug 3;101097JU00000000000003639. PMID: 37535836.
9. **Tan WS**, McElree IM, Davaro F, Steinberg RL, Bree K, Navai N, Dinney CP, O'Donnell MA, Li R, Kamat AM, Packiam VT. **Sequential Intravesical Gemcitabine and Docetaxel is an alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-Risk Non-muscle Invasive Bladder Cancer.** *Eur Urol Onc*. 2023. Jul 18;S2588-9311(23)00143-8. PMID: 37468392.
10. Contieri R, Grajales V, **Tan WS**, Martini A, Sood A, Hensley P, Bree K, Nogueras-Gonzalez GM, Guo CC, Navai N, Dinney CP, Kamat AM. **Impact of age >70 years on oncological outcomes in patients with NMIBC treated with BCG.** *BJU Int*. 2023 Jul 13. doi: 10.1111/bju.16127. PMID: 37442564.
11. **Tan WS**, Grajales V, Kelly B, Roger Li, Nogueras-Gonzalez G, Navai N, Dinney CP, Kamat AM. **BCG unresponsive non-muscle invasive bladder cancer: Are the sub-groups equal?** *BJU Int*. 2023 May 28. doi: 10.1111/bju.16087. PMID: 37246493.
12. **Tan WS**, Grajales V, Contieri R, Hensley P, Bree K, Msaouel P, Guo CC, Nogueras-Gonzalez G, Navai N, Dinney CP, Kamat AM. **Bladder sparing treatment in patients with BCG unresponsive non-muscle invasive bladder cancer: An analysis of long-term survival outcomes.** *Eur Urol Open Sci*. 2023 May 13;53:16-22. PMID: 37441349.
13. Khetrpal P, Wong JKL, Tan WP, Rupasinghe T, **Tan WS**, Williams S, Boorjian SA, Wijburg C, Parekh DJ, Wiklund P, Vasdev N, Khan MS, Guru KA, Catto JWF, Kelly JD. **Robot-assisted Radical**

- Cystectomy versus Open Radical Cystectomy: A systematic review and meta-analysis of perioperative, oncologic and quality of life outcomes using randomized controlled trials.** *Eur Urol* 2023 May 9;S0302-2838(23)02726-4. PMID: 37169638.
14. **Tan WS**, Koelker M, Campaign N, Cole AP, Labban M, Mossanen M, Barod R, Kibel AS, Chang SL, Bex A, Trinh QD. **Comparing long-term outcomes of young and healthy cT1a and cT3a renal cell carcinoma patients treated with partial nephrectomy.** *Eur Urol Focus.* 2022 Oct 11;S2405-4569(22)00225-5. PMID: 36241545.
 15. Leow J*, **Tan WS***, Tan WP, Tan TW, VWS Chan, Tikkinen K, Kamat A, Sengupta S, Meng MV, Shariat S, Roupert M, Decaestecker K, Vasdev N, Chong YL, Enikeev D, Gianluca G, Ficarra V, Teoh JYC. **A Systematic Review And Meta-Analysis On Delaying Surgery For Urothelial Carcinoma Of Bladder And Upper Tract Urothelial Carcinoma: Implications For The COVID19 Pandemic.** *Front Surg.* 2022 Oct 4;9:879774. PMID: 36268209.
 16. Tan WP, Bello AP, Alvarez G, Guerrero-Ramos F, González-Padilla DA, Nzeh C, de la Morena JM, de Torres IGV, Hendricksen K, Goizueta FJD, Del Alamo F, Chiancone F, Fedelini P, Poggio M, Corsiglia F, Rodríguez VCG, Torres JM, Wilby D, Robinson R, Sousa-Escandón A, Mata JL, Moreno JLP, Molina FD, Semino MAA, Calleja-Escudero J, Boormans JL, Redorta JP, **Tan WS.** **A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E.** *Bladder Cancer.* 2022. doi: 10.3233/BLC-220026.
 17. **Tan WS**, Prendergast A, Ackerman C, Yogeswaran Y, Cresswell, Mariappan P, Phull J, Hunter-Campbell P, Lazarowicz H, Mishra V, Rane A, Davies M, Warburton H, Cooke P, Mostafid H, Wilby D, Mills R, Issa R, Kelly JD. **Adjuvant intravesical chemohyperthermia versus passive chemotherapy in patients with intermediate risk non-muscle invasive bladder cancer (HIVEC II): A phase II, open label, randomized controlled trial.** *Eur Urol.* 2022 Aug 20;S0302-2838(22)02552-0. PMID: 35999119
 18. Hudson J, Cruickshank M, Quinton R, Aucott L. Aceves-Martins M, Gilles K, Bhasin S; Snyder P; Ellenberg S, Grossmann M, Travison T, Gianatti E, van der Schouw Y; Emmelot-Vonk M, Giltay E, Hackett G, Ramachandran S, Svartberg J, Hildreth K, Antonic KG, Brock G, Tenover JL, Tan HM, Ho CCK, **Tan WS**, Marks L, Ross R, Schwartz R, Manson P, Roberts S, Anderson M, Magnussen LV, Hernandez R, Oliver N, Wu F, Dhillon W, Bhattacharya S, Brazzelli M, Jayasena C. **Adverse cardiovascular events and mortality in men during testosterone treatment: results of individual patient and aggregate data meta-analyses.** *Lancet Healthy Longev.* 2022 Jun;3(6):e381-e393. PMID: 35711614.
 19. Cimadamore A, Teoh JY, di Trapani E, Krajewski W, **Tan WS**, Mori K, Del Giudice, Carrion DM, Moschini M. **A gender-related dichotomy in bladder cancer.** *Minerva Urol Nephrol.* 2022 Jun;74(3):376-378. PMID: 35607787.
 20. Kadhim H, Ang KM, **Tan WS**, Pavan N, Mazzon G, al-Kadhi O, Di G, Shaw G, Briggs T, Kelkar A, Rajan P, Nathan S, Kelly JD, Sooriakumaran P, Sridhar A. **Retzius sparing technique predicts early recovery of urinary continence after robot-assisted radical prostatectomy.** *J Robot Surg.* 2022 Feb 22. doi: 10.1007/s11701-022-01383-z. PMID: 35192106.
 21. Zhao H, Chan VWS, Castellani D, Chan EOT, Ong WLK, Peng Q, Moschini M, Krajewski W, Pradere B, Ng CF, Enikeev D, Vasdev N, Ekin G, Sousa A, Leon J, Guerrero-Ramos F, **Tan WS**, Kelly JD, Shariat SF, Witjes, Teoh JYC. **Intravesical chemohyperthermia versus Bacillus Calmette-Guerin instillation for intermediate- and high-risk non-muscle invasive bladder cancer: A systematic review and meta-analysis.** *Front Surg.* 2021 Nov 23;8:775527. doi: 10.3389/fsurg.2021.775527. PMID: 34888347.
 22. **Tan WS**, Leow JJ, Marchese, Sridhar A, Hellawell G, Mossanen M, Fowler S, Colquhoun AJ, Cresswell J, Catto JWF, Trinh QD, Kelly JD. **Defining factors associated with high-quality surgery following radical cystectomy: Analysis of the British Association of Urological Surgeons (BAUS) cystectomy audit.** *Eur Urol Open Sci.* 2021 Sep 20;33:1-10. doi: 10.1016/j.euros.2021.08.005. PMID: 34723215.

23. Chan VW-S*, **Tan WS***, Asif A, Ng A, Gbolahan O, Dinneen E, To W, Kadhim H, Premchand M, Burton O, Koe JS-E, Wang N, Leow JJ, Giannarini G, Vasdev N, Shariat SF, Enikeev D, Ng CF, Teoh JY-C. **Effects of Delayed Radical Prostatectomy and Active Surveillance on Localized Prostate Cancer—A Systematic Review and Meta-Analysis.** *Cancers (Basel)*. 2021 Jun 30;13(13):3274. doi: 10.3390/cancers13133274. PMID: 34208888.
24. Albisinni S, Moschini M, Di Trapani E, Soria F, Mari A, Aziz A, Teoh J, Laukhtina E, Mori K, D'Andrea D, Carrion DM, Krajewski W, Abufaraj M, Cimadamore A, **Tan WS**, Flippot R, Khalifa J, Gonsette K, Pradere B; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU). **Current application of the enhanced recovery after surgery protocol for patients undergoing radical cystectomy: lessons learned from European excellence centers.** *World J Urol*. 2021 Jun 2. doi: 10.1007/s00345-021-03746-x. PMID: 34076754.
25. Abozaid M, **Tan WS**, Khetrapal P, Baker H, Duncan J, Sridhar A, Briggs T, Selim M, Abdallah MM, Elmahdy AA, Elserafy F, Kelly JD. **Recovery of health-related quality of life in patients undergoing robotic radical cystectomy with intracorporeal diversion.** *BJU Int*. 2021 Jun 5. doi: 10.1111/bju.15505. PMID: 34092021.
26. Chan VW, **Tan WS**, Leow JJ, Tan WP, Ong WLK, Chiu PK, Gurung P, Pirola GM, Orecchia L, Liew MPC, Lee HY, Wang Y, Chen IA, Castellani D, Wroclawski ML, Mayor N, Sathianathan NJ, Braga I, Liu Z, Moon D, Tikkinen K, Kamat A, Meng M, Ficarra V, Giannarini G, Teoh JY. **Delayed Surgery for localized and metastatic renal cell carcinoma: a systematic review and meta-analysis for the COVID-19 pandemic.** *World J Urol*. 2021 May 24. doi: 10.1007/s00345-021-03734-1. PMID: 34031748.
27. **Tan WS**, Marchese M, Paciotti M, Nguyn DD, Cone EB, Mossanen M, Webster JJ, Barod R, Bex A, Kibel AS, Chang SL, Trinh QD. **Delay in surgery for cT1b-2 kidney cancer beyond 90 days is associated with poorer survival: Implications for prioritization during the COVID-19 pandemic.** *Minerva Urol Nephrol*. 2021. doi: 10.23736/S2724-6051.20.04197-1. PMID: 33781018.
28. **Tan WS**, Arianayagam R, Khetrapal P, Rowe E, Kearley S, Mahrous A, Fowler W, Heer R, Elajnaif M, Douglas-Moore, J, Griffiths TRL Voss J, Wilby D, Al-Kadhi O, Noel, J, Vasdev N, McKay A, Ahmad I, Abu-Nayla I, Lamb B, Hill GT, Narahari, K, Kynaston H, Yousuf A, Kusuma VRM, Cresswell J, Cooke P, Chakravarti A, Ravi B, Bex A, Kelly JD. **Major Urological Cancer Surgery for Patients is Safe and Surgical Training Should Be Encouraged During the COVID-19 Pandemic: A Multicentre Analysis of 30-day Outcomes.** *Eur Urol Open Sci*. 2021. <https://doi.org/10.1016/j.euros.2021.01.005>. PMID: 33458711.
29. Woldu SL, Ng CK, Loo RK, Slezak JM, Jacobsen SJ, **Tan WS**, Kelly JD, Lough T, Darling D, van Kessel KEM, de Jong JJ, van Criekinge W, Shariat SF, Hiar A, Brown S, Boorjian SA, Barocas DA, Svatek RS, Lotan Y. **Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria.** *J Urol*. 2020. <https://doi.org/10.1097/JU.0000000000001550>. PMID: 33356483
30. Mortezaei A, Crippa A, Edeling S, Pokupic S, Dell'Oglio P, Montorsi F, D'Hondt F, Mottrie A, Decaestecker K, Wijburg CJ, Collins J, Kelly JD, **Tan WS**, Sridhar A, John H, Canda AE, Schwentner C, Rönmark EP, Wiklund P, Hosseini A. **Morbidity and mortality after robot-assisted radical cystectomy with intracorporeal urinary diversion in octogenarians – results from the EAU Robotic Urology Section (ERUS) Scientific Working Group.** *BJU Int* 2020. Oct. Doi: <https://doi.org/10.1111/bju.15274>. PMID: 33058469.
31. Ahmed Y, Hussein AA, May PR, Ahmad B, Khan A, Benowski J, Durrani A, Khan S, Kozlowski J, Saar M, Wijburg CJ, Richstone L, Wagner A, Yuh B, Redorta JP, Dasgupta P, Shamim Khan M, Menon M, Peabody JO, Hosseini A, Gaboardi F, Pini G, Schanne F, Mottrie A, Rha KH, Hemal A, Stockle M, Kelly J, **Tan WS**, Maatman TJ, Poulakis V, Kaouk J, Canda AE, Balbay MD, Wiklund P, Guru KA. **Quality of surgical care can impact survival in patients with bladder cancer after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium.** *Afr J Urol*. 2020 June 22: 10.1186/s12301-020-00031-y.

32. **Tan WS**, Wang Ye, Trinh QD, Preston MA, Kelly JD, Hrouda D, Kibel AS, Krasnow RE, Liu JJ, Chung BI, Chang SL, Mossanen M. **Delayed blood transfusion is associated with mortality following radical cystectomy.** *Scand J Urol.* 2020 Jun 13;1-7. PMID: 32538224.
33. Berg S, Tully K, Sahraoui A, **Tan WS**, Krimphove MJ, Marchese M, Lipsitz S, Noldus J, Trinh QD. **Inequity in selective referral to high-volume hospitals for genitourinary malignancies.** *Urol Oncol.* 2020 Jun;38(6):582-589. PMID: 32217041.
34. **Tan WS**, Teo CH, Chan D, Heinrich M, Feber A, Sarpong R, Allan J, Williams N, Brew-Graves C, Ng CJ, Kelly JD; DETECT II trial collaborators. **Exploring patients' experience and perception of being diagnosed with bladder cancer: A mixed methods approach.** *BJU Int.* 2020 May;125(5):669-678. PMID: 31975539.
35. **Tan WS**, Trinh QD, Hayn MH, Marchese M, Lipsitz SR, Nabi J, Kilbridge KL, Vale JA, Khoubehi B, Kibel AS, Sun M, Chang S, Sammon JD. **Delayed Nephrectomy Has Comparable Long-Term Overall Survival to Immediate Nephrectomy for cT1a Renal Cell Carcinoma: A Population-Based Analysis.** *Urol Oncol.* 2020 Mar;38(3):74.e13-74.e20. PMID 31864937.
36. Cox E, Saramago P, Kelly JD, Porta N, Hall E, **Tan WS**, Sculpher M, Soares M. **The Impacts of Bladder Cancer on UK Healthcare Costs and Patients' Health-Related Quality of Life: Evidence from the BOXIT Trial.** *Clin Genitourin Cancer.* 2020 Aug;18(4):e418-e442. PMID: 32144049.
37. Jubber I, Shariat SF, Conroy S, **Tan WS**, Gordon PC, Lotan Y, Messing EM, Stenzl A, van Rhijn B, Kelly JD, Catto JWF, Cumberbatch MG. **Non-visible hematuria for the Detection of Bladder, Upper Tract, and Kidney Cancer: An Updated Systematic Review and Meta-analysis.** *Eur Urol.* 2020 May;77(5):583-598. PMID 31791622.
38. Tan WP, **Tan WS**, Inman B. **PD-L1/PD-1 Biomarker for Metastatic Urothelial Cancer that Progress Post-platinum Therapy: A Systematic Review and Meta-analysis.** *Bladder Cancer.* 2019 Nov 22;5(3):211-223. PMID 31867425.
39. Moschini M, Zamboni S, Soria F, Mathieu R, Xylinas E, D'Andrea D, **Tan WS**, Kelly JD, Simone G, Meraney A, Krishna S, Konety B, Zamboni S, Mattei A, Mondorsi F, Briganti A, Rink M, Karakiewicz PI, Roupert M, Perry M, Rowe E, Koupparis A, Kassouf W, Scherr DS, Ploussard G, Boorjian SA, Lotan Y, Sooriakumaran P, Shariat SF. **Open versus robotic cystectomy: a propensity score matched analysis comparing survival outcomes.** *J Clin Med.* 2019 Aug 9;8(8). pii: E1192. PMID: 31395826.
40. **Tan WS**, Krimphove MJ, Cole AP, Berg S, Marchese M, Lipsitz SR, Löppenberg B, Nabi J, Abdollah F, Choueiri TK, Kibel AS, Sooriakumaran P, Trinh QD. **Variation in positive surgical margin status following radical prostatectomy for pT2 prostate cancer.** *Clin Genitourin Cancer.* 2019 Oct;17(5):e1060-e1068. PMID: 31303561.
41. Zamboni S, Soria F, Mathieu R, Xylinas E, Abufaraj M, D'Andrea D, **Tan WS**, Kelly JD, Simone G, Gallucci M, Meraney A, Krishna S, Konety BR, Antonelli A, Simeone C, Baumeister P, Mattei A, Briganti A, Gallina A, Montorsi F, Rink M, Aziz A, Karakiewicz PI, Roupert M, Koupparis A, Scherr DS, Ploussard G, Sooriakumaran P, Shariat SF, Moschini M; European Association of Urology - Young Academic Urologists (EAU-YAU) Urothelial carcinoma working group; EAU Research Foundation. **Differences in utilization-trend and time changes of peri-operative outcomes of robotic and open radical cystectomy between American and European selected centers: an international multicenter collaboration.** *BJU Int.* 2019 May 4. doi: 10.1111/bju.14791. PMID: 31055865.
42. Thompson JE, Sridhar AN, **Tan WS**, Freeman A, Haider A, Allen C, Moore CM, Orzcyk C, Mazzone G, Khetrpal P, Shaw G, Rajan P, Mohammed A, Briggs TP, Nathan S, Kelly JD, Sooriakumaran P. **Pathologic findings and MRI concordance at salvage radical prostatectomy for local recurrence following partial ablation using high-intensity focused ultrasound.** *J Urol.* 2019. Jun;201(6):1134-1143. PMID: 30730409.

43. **Tan WS**, Teo CH, Chan D, Heinrich M, Feber A, Sarpong R, Allan J, Williams N, Brew-Graves C, Ng CJ, Kelly JD; DETECT II trial collaborators. **Mix methods approach to explore patients' perspectives on the acceptability of a urinary biomarker test in replacement of cystoscopy in bladder cancer surveillance.** *BJU Int.* 2019 Sep;124(3):408-417. PMID: 30694612.
44. **Tan WS**, Ahmad A, Feber A, Mostafid H, Cresswell J, Fankhauser CD, Waisbrod S, Hermanns T, Sasieni P, Kelly JD; DETECT I trial collaborators. **Development and validation of a hematuria cancer risk score to identify patients at risk of harboring cancer.** *J Intern Med.* 2019 Apr;285(4):436-445. PMID: 30521125.
45. Mossanen M, Krasnow RE, Zlatev DV, **Tan WS**, Preston MA, Trinh QD, Kibel AS, Sonpavde G, Schrag D, Chung BI, Chang SL. **Examining the relationship between complications and perioperative mortality following radical cystectomy: A population-based analysis.** *BJU Int.* 2019 Jul;124(1):40-46. PMID: 30499636.
46. Mossanen M, Wang Y, Szymaniak J, **Tan WS**, Huynh MJ, Preston MA, Trinh QD, Sonpavde G, Kibel AS, Chang SL. **Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories.** *World J Urol* 2019 Oct;37(10):2059-2065. PMID: 30446799.
47. Moschini M, Soria F, Mathieu R, Xylinas E, D'Andrea D, **Tan WS**, Kelly JD, Simone G, Meraney A, Krishna S, Konety B, Zamboni S, Mattei A, Mondorsi F, Briganti A, Rink M, Karakiewicz PI, Roupert M, Perry M, Rowe E, Koupparis A, Kassouf W, Scherr DS, Ploussard G, Boorjian SA, Lotan Y, Sooriakumaran P, Shariat SF. **Propensity-score matched comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy.** *Urol Oncol.* 2019 Mar;37(3):179.e1-179.e7. PMID: 30446442.
48. **Tan WS**, Panchal A, Buckley L, Devall AJ, Loubiere LS, Pope AM, Feneley MR, Cresswell J, Issa R, Mostafid H, Madaan A, Bhatt R, McGrath J, Sangar V, Griffiths TRL, Page T, Hodgson D, Datta SN, Bilingham LJ, Kelly JD. **Radiofrequency-induced thermo-chemotherapy effect (RITE) versus a second course of bacillus Calmette-Guérin (BCG) or institutional standard in patients with recurrence of non-muscle invasive bladder cancer following induction or maintenance BCG therapy (HYMN): A phase III, open-label, randomized controlled trial.** *Eur Urol.* 2019 Jan;75(1):63-71. PMID: 30274699.
49. Kelly JD*, **Tan WS***, Porta N, Mostafid H, Huddart R, Protheroe A, Bogle R, Blazeby J, Palmer A, Cresswell J, Johnson M, Brough R, Madaan A, Andrews S, Cruickshank C, Burnett S, Maynard L, Hall E. **BOXIT – A randomized phase III placebo-controlled trial evaluating the addition of celecoxib to standard treatment of transitional cell carcinoma of the bladder (CRUK/07/004).** *Eur Urol.* 2019 Apr;75(4):593-601. PMID: 30279015.
50. Wong YNS, Joshi K, Khetrpal P, Ismail M, Reading JL, Sunderland MW, Georgiou A, Furness AJS, Ben Aissa A, Ghorani E, Oakes T, Uddin I, **Tan WS**, Feber A, McGovern U, Swanton C, Freeman A, Marafioti T, Briggs TP, Kelly JD, Powles T, Peggs KS, Chain BM, Linch MD, Quezada SA. **Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment.** *J Exp Med.* 2018 Nov 5;215(11):2748-2759. PMID: 30257862.
51. **Tan WS**, Sarpong R, Khetrpal P, Rodney S, Mostafid H, Cresswell J, Watson D, Rane A, Hicks J, Hellawell G, Davies M, Srirangam SJ Dawson L, Payne D, Williams N, Brew-Graves C, Feber A, Kelly JD, on behalf of DETECT I trial collaborators. **Does urinary cytology have a role in hematuria investigations?** *BJU Int.* 2019 Jan;123(1):74-81. PMID: 30003675.
52. **Tan WS**, Tan WP, Tan MY, Khetrpal P, Dong Liqin, deWinter P, Feber A, Kelly JD. **Novel urinary biomarker for the detection of bladder cancer: A systematic review.** *Cancer Treat Rev.* 2018 Sept; 69: 39-52. PMID: 29902678.
53. Khetrpal P, Lee MWL, **Tan WS**, Dong Liqin, deWinter P, Feber A, Kelly JD. **The role of circulating tumor cells and nucleic acids in blood for the detection of bladder cancer.** A systematic review. *Cancer Treat Rev.* 2018 Apr 17;66:56-63. PMID: 29684744.

54. **Tan WS**, Sarpong R, Khetrapal P, Rodney S, Jalil R, Mostafid H, Cresswell J, Hicks J, Rane A, Henderson A, Watson D, Cherian J, Williams N, Brew-Graves C, Feber A, Kelly JD, on behalf of DETECT I trial collaborators. **Can renal and bladder ultrasound replace CT urogram in patients investigated for microscopic hematuria.** *J Urol.* 2018 Nov;200(5):973-980. PMID: 29702097.
55. **Tan WS**, Feber A, Sarpong R, Khetrapal P, Rodney S, Jalil R, Mostafid H, Cresswell J, Hicks J, Rane A, Henderson A, Watson D, Cherian J, Williams N, Brew-Graves C, Kelly JD, on behalf of DETECT I trial collaborators. **Who should be investigated for hematuria? Results of a contemporary prospective observational study of 3556 patients.** *Eur Urol.* 2018 Jul;74(1):10-14. PMID: 29653885.
56. Hussein AA, May PR, Jing Z, Ahmed YE, Wijburg CJ, Canda AE, Dasgupta P, Shamim Khan M, Menon M, Peabody JO, Hosseini A, Kelly J, Mottrie A, Kaouk J, Hemal A, Wiklund P, Guru KA; Collaborators, Wagner A, Saar M, Redorta JP, Stockle M, Richstone L, Gaboardi F, Badani K, Rha KH, Khan H, Kawa O, Schanne F, Polakis V, Weizer A, Scherr D, Pini G, **Tan WS**, Maatman TJ, Kibel A, Yuh B, Peak TC. **Outcomes of Intracorporeal Urinary Diversion after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium.** *J Urol.* 2018 May;199(5):1302-1311. PMID: 29275112.
57. **Tan WS**, Feber A, Dong L, Sarpong R, Razaee S, Rodney S, Khetrapal P, de Winter P, Ocampo F, Falil R, Williams N, Brew-Graves C, Kelly JD. **DETECT I & DETECT II: A Study Protocol for a Prospective Multicenter Observational Study to Validate the UroMark Assay for the Detection of Bladder Cancer from Urinary Cells.** *BMC Cancer.* 2017 Nov 15;17(1):767. PMID: 29141603.
58. **Tan WS**, Tan MY, Lamb BW, Sridhar A, Mohammed A, Baker H, Nathan S, Briggs T, Tan MEL, Kelly JD. **Intracorporeal robotic assisted radical cystectomy together with an enhanced recovery program improves postoperative outcomes by aggregating marginal gains.** *BJU Int.* 2018 Apr;121(4):632-639. PMID: 29124853.
59. Hussein AA, May PR, Ahmed YE, Saar M, Wijburg CJ, Richstone L, Wagner A, Wilson T, Yuh B, Redorta JP, Dasgupta P, Kawa O, Khan MS, Menon M, Peabody JO, Hosseini A, Gaboardi F, Pini G, Schanne F, Mottrie A, Rha KH, Hemal A, Stockle M, Kelly J, **Tan WS**, Maatman TJ, Poulakis V, Kaouk J, Canda AE, Balbay MD, Wiklund P, Guru KA. **Development of a patient and institutional-based model for estimation of operative times for robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium.** *BJU Int.* 2017 Nov;120(5):695-701. PMID: 28620985.
60. **Tan WS**, Lamb BW, Khetrapal P, Tan MY, Tan MEL, Sridhar A, Cervi E, Rodney S, Busuttil G, Nathan S, Hines J, Shaw G, Mohammed A, Baker H, Briggs TP, Klein A, Richards T, Kelly JD. **Blood Transfusion Requirement and not Preoperative Anemia is associated with Perioperative Complications following Intracorporeal Robotic Assisted Radical Cystectomy.** *J Endourol.* 2017 Feb;31(2):141-148. PMID: 27901350.
61. Feber A, Dhami P, Dong L, de Winter P, **Tan WS**, Martinez-Fernande M, Paul D, Hynes-Allen A, Rezaee S, Gurung P, Rodney S, Mehmood A, Villacampa F, de la Rosa F, Jameson C, Cheng KK, Zeegers MP, Bryan RT, James ND, Paramio JM, Freeman A, Beck S, Kelly JD. **UroMark - A urinary biomarker assay for the detection of bladder cancer.** *Clin Epig.* 2017 Jan 31;9:8. PMID: 28163793.
62. Hussein AA, Saar M, May PR, Wijburg CJ, Richstone L, Wagner A, Wilson T, Yuh B, Redorta JP, Dasgupta P, Shamim Khan M, Menon M, Peabody JO, Hosseini A, Gaboardi F, Mottrie A, Rha KH, Hemal A, Stockle M, Kelly J, Maatman TJ, Canda AE, Balbay MD, Poulakis V, Woods M, **Tan WS**, Kawa O, Pini G, Badani K, Ahmed YE, Wiklund P, Guru KA. **Early Oncologic Failure after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium.** *J Urol* 2017 Jun;197(6):1427-1436. PMID:27993668.
63. **Tan WS**, Khetrapal P, Tan WP, Rodney S, Chau M, Kelly JD. **A Systematic Review and Meta-analysis of Randomized Controlled Trials of Robotic Assisted Radical Cystectomy versus Open Radical Cystectomy.** *PLoS One.* 2016 Nov 7;11(11):e0166221. PMID: 27820855.

64. Feber A, Worth D, Chakravarthy A, de Winter P, Shah K, Arya M, Saqib M, Nigam R, Malone P, **Tan WS**, Rodney S, Freeman A, Jameson C, Wilson G, Powles T, Beck B, Fenton T, Sharp T, Muneer A, Beck S, Kelly JD. **CSN1 somatic mutations in penile squamous cell carcinoma.** *Cancer Res.* 2016 Aug 15;76(16):4720-7. PMID: 27325650.
65. **Tan WS**, Lamb BW, Tan MY, Ahmad I, Sridhar A, Nathan S, Shaw G, Hines J, Briggs T, Kelly JD. **Complications following Robotic Assisted Radical Cystectomy with Intracorporeal Urinary Diversion: An in Depth Critical Analysis of Technical and Systemic Complications.** *Eur Urol Focus.* 2017 Apr;3(2-3):273-279. PMID: 28753745.
66. Khetrpal P, **Tan WS**, Lamb B, Nathan S, Briggs T, Shankar A, Ramachandran N, Freeman A, Mitra A, Kelly JD. **Port-site metastases following robotic radical cystectomy: A systematic review and management options.** *Clin Genitourin Cancer.* 2017 Aug;15(4):440-444. PMID: 28209455.
67. Lamb BW, **Tan WS**, Eneje P, Bruce D, Jones A, Ahmad I, Sridhar A, Baker H, Briggs T, Hines JE, Nathan S, Martin D, Stephens R, Kelly JD. **Benefits of robotic cystectomy with intracorporeal diversion for patients with low cardiorespiratory fitness: a prospective cohort study.** *Urol Oncol.* 2016 Sep;34(9):417.e17-23. PMID: 27197920.
68. **Tan WS**, Sridhar A, Ellis G, Lamb BW, Goldstraw M, Nathan S, Hines J, Cathcart P, Briggs T, Kelly JD. **Analysis of open and intracorporeal robotic cystectomy shows no significant difference in recurrence patterns and oncological outcomes.** *Urol Oncol.* 2016 Jun;34(6):257.e1-9. PMID:26968561.
69. Tan WK, Tan MY, **Tan WS**, Gan SC, Pathmanathan R, Tan HM, Tan WP. **Well-differentiated Papillary Mesotheliomas of the Tunica Vaginalis: Care Report and Systematic Review of Literature.** *Clin Genitourin Cancer.* 2016 Aug;14(4):e435-9 : 27067374. PMID: 27067374
70. Feber A, Arya M, de Winter P, Saqib M, Nigam R, Malone P, **Tan WS**, Rodney S, Freeman A, Jameson C, Muneer A, Beck S, Kelly JD. **Epigenetics markers of metastasis and HPV induced tumourigenesis in penile cancer.** *Clin Cancer Res.* 2015 Mar 1;21(5):1196-206. PMID:25538261.
71. **Tan WS**, Sridhar A, Goldstraw M, Zacharakis E, Nathan S, Hines J, Cathcart P, Briggs T, Kelly JD. **Robot Assisted Intracorporeal Pyramid Neo-bladder.** *BJU Int.* 2015 Nov;116(5):771-9. PMID:26033321.
72. Lamb BW*, **Tan WS***, Rehman A, Nessa A, O'Neil J, Cohen D, Green JS, Hines JE. **Is pre-biopsy MRI good enough to avoid prostate biopsy? A cohort study over a 1 year period.** *Clin Genitourin Cancer.* 2015 Dec;13(6):512-7. PMID:26231912.
73. **Tan WS**, Lamb BW, Payne H, Hughes S, Green JSA, Lane T, Adshead J, **Boustead G**, **Vasdev N**. **Management of node positive bladder cancer following neo-adjuvant chemotherapy and radical cystectomy: A survey of current UK practice.** *Clin Genitourin Cancer.* 2015 Jun;13(3):e153-8. PMID:25510376.
74. Gurung PM, Veerakumarasivam A, Williamson M, Counsell N, Douglas J, **Tan WS**, Feber A, Crabb S, Short SC, Freeman A, Powles T, Hoskin PJ, West CM, Kelly JD. **Loss of Expression of the Tumor Suppressor Gene AIMP3 Predicts Survival Following Radiotherapy in Muscle-Invasive Bladder Cancer.** *Int J Cancer.* 2015 Feb 1;136(3):709-20. PMID:24917520.
75. **Tan WS**, Low WY, Ng CJ, Khoo EM, Ho E, Tan HM. **Overactive bladder (OAB) and its association with Prostatic Parameters.** *J Men's Health.* 2013 Dec; 8 (S1): S71-S74. doi:10.1016/S1875-6867(11)60026-2.
76. **Tan WS**, Ho CCK, Tong SF, Tan WK, Ng CJ, Low WY, Khoo EM, Tan HM. **Efficacy and Safety of Long-acting Intramuscular Testosterone Undecanoate in Aging Men: a Randomized Controlled Study.** *BJU Int.* 2013 Jun;111(7):1130-40. PMID:23651425.

77. **Tan WS, Ng CJ, Khoo EM, Low WY, Tan HM. The Triad of Erectile Dysfunction, Hypogonadism and Metabolic Syndrome – Findings from a Multiethnic Asian Men Study. *Aging Male*. 2011 Dec;14(4):231-6. PMID:22115177.**

Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

1. Li R, Hensley PJ, Gupta S, Al-Ahmadie H, Babjuk M, Black PC, Brausi M, Bree KK, Fernández MI, Guo CC, Horowitz A, Lamm DL, Lerner SP, Lotan Y, Mariappan P, McConkey D, Mertens LS, Mir C, Ross JS, O'Donnell M, Palou J, Pohar K, Steinberg G, Soloway M, Spiess PE, Svatek RS, **Tan WS**, Taoka R, Buckley R, Kamat AM. **Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection. *Eur Urol*. 2024 Aug 24:S0302-2838(24)02516-8. PMID: 39183090.**
2. **Tan WS, Hall E, Kamat AM, Kelly JD. Clinical trial design for non-muscle invasive bladder cancer. *Nat Rev Urol*. 2023 Jun 16. doi: 10.1038/s41585-023-00789-0. PMID: 37328547.**
3. **Tan WS, Tan MY, Alhalabi O, Campbell MT, Kamat AM, Gao JJ. Evolving Systemic Management of Urothelial Cancers. *Curr Opin Oncol* 2023 Mar 15. doi: 10.1097/CCO.0000000000000942. PMID: 36966497.**
4. Hensley PJ, Lobo N, Bree KK, **Tan WS**, Gontero P, Williams SB, Guo CC, Giannarini G, Dyrskjot L, Kamat AM. **Predictive Biomarkers for Urothelial Carcinoma of the Bladder: Perspectives in an Evolving Therapeutic Landscape. *SIUJ* 2022 July 3 (4): 245-257.**
5. **Tan WS, Steinberg G, Witjes JA, Li R, Shariat SF, Roupert M, Babjuk M, Bivalacqua TJ, Psutka SP, Williams SB, Cookson MS, Palou J, Kamat AM. Intermediate risk non muscle invasive bladder cancer: updated consensus definition and management recommendations from the International Bladder Cancer Group (IBCG). *Eur Urol Oncol*. 2022 Jun 16;S2588-9311(22)00088-8. PMID: 35718695.**
6. **Tan WS, Kelly JD. Device Assisted Therapies for Bladder Cancer. *Nat Rev Urol*. 2018 Nov;15(11):667-685. PMID: 30254383.**
7. Khetrapal P, **Tan WS**, Lamb B, Tan M, Baker H, Thompson J, Sridhar A, Kelly JD, Briggs T. **The Role of Robotics in the Invasive Management of Bladder Cancer. *Curr Urol Rep*. 2017 Aug;18(8):57. PMID: 28634646.**
8. **Tan WS, Lamb BW, Sridhar A, Briggs TP, Kelly JD. A comprehensive guide to perioperative management and operative technique for robotic cystectomy with intracorporeal urinary diversion. *Urologia*. 2017 Apr 28;84(2):71-78. PMID: 28256704.**
9. **Tan WS, Rodney S, Lamb BW, Feneley M, Kelly JD. Management of Non-muscle Invasive Bladder Cancer: A Comprehensive Analysis of Guidelines from the United States, Europe and Asia. *Cancer Treat Rev*. 2016 May 10;47:22-31. PMID: 27231966.**
10. **Tan WS, Lamb BW, Kelly JD. Complications of Radical Cystectomy and Orthotopic Reconstruction. *Adv Urol*. 2015; 323157. PMID:26697063.**
11. **Tan WS, Lamb BW, Kelly JD. Evolution of Neobladder Reconstruction: A Critical Review of Open and Intracorporeal Neobladder Reconstruction Techniques. *Scand J Urol*. 2016 Feb 16:1-9. PMID:26882458.**

Peer-Reviewed Educational Materials

1. **Tan WS, Kamat AM. Case Presentation: High Grade Recurrence After BCG for Non-Muscle Invasive Bladder Cancer. Oncology Learning Network. 2022. [URL: <https://rb.gy/yukja>].**
2. **Tan WS. T1 Bladder Cancer. The Leo & Anne Albert Institute for Bladder Cancer Care and Research (AIBCCR) 8th Annual Symposium. 2022. UroToday. [URL: <https://rb.gy/pome0>].**

3. **Tan WS. Cell-free DNA, Circulating Tumor Cells, Exosomes and Bladder Cancer.** The Leo & Anne Albert Institute for Bladder Cancer Care and Research (AIBCCR) 8th Annual Symposium. 2022. UroToday [URL: <https://rb.gy/exj4f>].

Peer-Reviewed Case Reports and Technical Notes

1. Myers AA, **Tan WS**, de Groot J, Westney OL, Kamat AM. 'Case of the Month' from The University of Texas MD Anderson Cancer Center, Houston, Texas, USA: ependymoma of the urinary bladder. *BJU Int.* 2024 Feb 20. doi: 10.1111/bju.16302. PMID: 38379218.
2. Mukherjee S, Sinha RK, Mandal SN, **Tan WS**. **Primary urethral tuberculosis with urethrocutaneous fistula in association with balanitis xerotica obliterans.** *Urology.* 2020 Jul;141:e20-e21. PMID: 32325139.
3. Mukherjee S, Sinha RK, Mandal SN, **Tan WS**. **Spontaneous ureterocutaneous fistula secondary to obstructed ureteric stone.** *Urology.* 2020 Apr;138:e5-e7. PMID: 31958535.

Book Chapters

1. **Tan WS**, Ta A, Sridhar A, Kelly JD. **Male Robotic Cystectomy with nerve sparing technique.** *Robotic Urology.* 4th edition. Editors: Hubert J, Wiklund P. Springer. New York.
2. Weyne E, **Tan WS**, Kelly, JD, Sridhar A. **Intracorporeal Neobladder- UCLH experience.** *Robotic Urology Surgery.* Editor: Patel V. Springer. New York.
3. **Tan WS**, Sridhar A, Kelly JD. **Male Robotic Cystectomy.** *Robotic Urology.* 3rd edition. Editors: Hubert J, Wiklund P. Springer. New York.
4. Lamb BW, Li CY, **Tan WS**, Green JSA. **Management of Hematuria in Patients with Prostate Cancer. Hematuria- Etiology, Management and Long Term Prognosis.** Editors: Vasdev N, Boustead G. Nova Books, New York.

Commentaries, Editorials, and Letters

1. **Tan WS**, O'Donnell MA, Li R, Kamat AM, Packiam VT. **Reply to Wen-Wei Sung's Letter to the Editor Re: Wei Shen Tan, Ian M. McElree, Facundo Davaro, et al. Sequential Intravesical Gemcitabine and Docetaxel Is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer.** *Eur Urol Oncol.* 2023;6:531-534. *Eur Urol Oncol.* 2024 Feb; 7(1): 164-65.
2. **Tan WS**, Contieri R, Buffi NM, Lughezzani G, Grajales V, Soloway M, Casale P, Hurle R, Kamat AM. **Reply by Authors.** *J Urol.* 2023 Nov;210(5):770. PMID: 37622536.
3. Heer R, **Tan WS**, Gravestock P, Vadiveloo T, Lewis R, Penegar, Vale L, MacLennan G, Hall E, PHOTO trial team. **Reply to Arnulf Stenzl, Morgan Rouprêt, J. Alfred Witjes, Paolo Gontero. High-quality Transurethral Resection of Bladder Tumor Needs Additional Forms of Tumor Delineation.** *Eur Urol* 2023;83:193-4. *Eur Urol* 2023. *Eur Urol.* 2024 Mar;85(3):309-312. PMID: 37330372.
4. **Tan WS**, Mustard C, Kelly JD, HIVEC-II trial team. **Reply to Suman Sahoo, Abhishek Pandey, Swarnendu Mandal, Manoj Kumar Das, Prasant Nayak's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open label, Randomized Controlled Trial.** *Eur Urol.* *Eur Urol* 2023 Feb;83(2):e48-e49. PMID: 36456403.
5. **Tan WS**, Kelly JD, HIVEC-II trial team. **Reply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomized Controlled Trial.** *Eur Urol.* *In press.* *Eur Urol* 2023 Jan;83(1):e29-e30. PMID: 36272948.
6. Khetrpal P, Wong JKL, Tan WP, Rupasinghe T, **Tan WS**, Williams SB, Boorjian SA, Wijburg C, Parekh DJ, Wiklund P, Vasdev N, Khan MS, Guru KA, Catto JWF, Kelly JD. **Corrigendum to "Robot-**

- assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Controlled Trials" [Eur Urol. 2023;84:393-405]. *Eur Urol.* 2023 Oct;84(4):e98-e99. PMID: 37562989.**
7. **Tan WS, Ta A, Sridhar A, Kelly JD. Organ sparing radical cystectomy- Improving functional outcomes. *Trends Urol Men Health.* May 2022. doi: <https://doi.org/10.1002/tre.875>.**
 8. **Tan WS, Kelly JD. Robotic surgery: Getting the evidence right. *Med J Aust.* 2022 Oct 17;217(8):391-393. PMID: 36183333.**
 9. **Tan WS, Kelly JD. Is delay to radical cystectomy following BCG failure oncologically safe? *Nat Rev Urol.* 2021. doi: 10.1038/s41585-021-00457-1. PMID: 33772157.**
 10. **Tan WS, Wong A, Mahmalji W, Raza A. Is there a still a role for digital rectal examination in the prostate cancer diagnostic pathway in the Covid-19 and post Covid-19 era? *Aging Male.* 2020. <https://doi.org/10.1080/13685538.2020.1786047>.**
 11. **Tan WS, Kelly JD. Editorial comment: A Urine Based Genomic Assay to Triage Patients with Hematuria for Cystoscopy. *J Urol.* 2020 Apr 13;101097JU0000000000000078602. PMID: 32282283**
 12. **Tan WP, Kelly JD, Tan WS. Bladder cancer and hematuria. *Trends Urol Men Health.* April 2019**
 13. **Tan WS, Kelly JD. Is experience with extracorporeal diversion following robotic assisted radical cystectomy necessary before transitioning to intracorporeal urinary diversion? *Transl Androl Urol.* 2018 Dec;7(Suppl 6):S735-S737 PMID: 30687611**
 14. **Tan WS, Tan WP. Urinary biomarker for the detection of recurrence following non-muscle invasive bladder cancer: Are we there yet? *Transl Androl Urol.* 2018 Mar;7(Suppl 1):S109-S110. PMID: 29644175.**
 15. **Khetrapal P, Tan WS, Kelly JD. Factors affecting the cost of radical cystectomy in the USA: some centers are more equal than others. *Eur Urol.* 2018 Mar;73(3):383-384. PMID: 29174579.**